December 9, 2015
Whom It May Concern
Company:KYORIN Holdings, Inc.
Representative: Minoru Hogawa
Representative Director, President(Security Code: 4569, TSE 1st Sec.)Contact:Shuji Miyaki
Director, Corporate Communication
President OfficeTelephone:(0)3-3525-4707

Kyorin Pharmaceutical Signed a License Agreementwith Bristol-Myers Squibb
TOKYO, Japan – December 9, 2015 - KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku,Tokyo, President and Chief Executive Officer: Mitsutomo Miyashita, “Kyorin Pharmaceutical”), a
wholly-owned subsidiary of KYORIN Holdings, Inc., has announced a license agreement withBristol-Myers Squibb Company (Head office: New York, Chief Executive Officer: Giovanni Caforio)
for Kyorin Pharmaceutical’s FPR2 agonist program*.
Under the terms of the agreement, Kyorin Pharmaceutical grants Bristol-Myers Squibb exclusive
worldwide license to develop, manufacture and commercialize products within the program and inreturn, Bristol-Myers Squibb will make an upfront payment of US$35 million. Kyorin Pharmaceutical
will be also eligible to receive up to US$370 million in development and regulatory milestones, alongwith royalties on net sales and sales based milestones. Kyorin Pharmaceutical will have an option tocollaborate with Bristol-Myers Squibb in the development and commercialization in Japan.
Bristol-Myers Squibb is committed to the development of Kyorin’s promising novel therapeutics
against this target for undisclosed indications so as to rapidly introduce the same to the global markets.
Kyorin Pharmaceutical believes that the partnering with Bristol-Myers Squibb will accelerate theglobal development of its original novel therapeutics meeting medical needs, which will lead to theearly contribution to the health of people in the world as well as the maximization of the value ofKyorin Pharmaceutical’s own program.
Kyorin Pharmaceutical will record the revenue of the upfront payment of US$35 million in this fiscalyear (ending March 2016), the impact of which on its consolidated financial results will be announced
once it has been confirmed.
###* FPR stands for Formyl peptide receptor, G protein-coupled receptor. FPR-2 agonists mainly inhibit themigration of neutrophils and exhibit anti-inflammatory action.

About Bristol-Myers Squibb
Established in:CEO:
Revenue:
No. of Employees:
Overview:

1858
Giovanni Caforio, M.D.
USD 15.9 billion (Fiscal Year ending December 2014)
Approx. 25,000 (as of December 31, 2014)
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help patientsprevail over serious diseases. For more information, please visit
www.bms.com or follow them on Twitter at http://twitter.com/bmsnews.

About KYORIN Pharmaceutical
Established in:
President & CEO:
Revenue:
No. of Employees:
Overview:

December 1923
Mitsutomo Miyashita, Ph.D.
JPY 98,452 million (Fiscal Year ending March 2015)
1,771 (as of March 31, 2015)
Trusted among patients and professionals in the medical industry, KYORIN
Pharmaceutical strives to be a company that contributes to the public healthand is recognized as a one with social significance by improving its presencein specified therapeutic areas and through global discovery of novel drugs.
KYORIN Pharmaceutical uses its franchise customer strategy in focusing on
respiratory medicine, otolaryngology and urology, and concentrates
resources on the core areas of respiratory, otolaryngological and urologicaldiseases in developing ethical drugs.